Cryo-Cell International, Inc. (CCEL)
NYSEAMERICAN: CCEL · Real-Time Price · USD
3.650
-0.500 (-12.05%)
Oct 15, 2026, 4:00 PM EDT - Market closed
Cryo-Cell International Income Statement
Financials in millions USD. Fiscal year is December - November.
Millions USD. Fiscal year is Dec - Nov.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 31, 2026 | Nov '25 Nov 30, 2025 | Nov '24 Nov 30, 2024 | Nov '23 Nov 30, 2023 | Nov '22 Nov 30, 2022 | Nov '21 Nov 30, 2021 |
| 31.13 | 31.57 | 31.99 | 31.34 | 30.34 | 28.88 | |
Revenue Growth | -1.96% | -1.31% | 2.05% | 3.32% | 5.03% | -7.26% |
Cost of Revenue | 11.04 | 11.74 | 7.95 | 12.13 | 8.79 | 10.15 |
Gross Profit | 20.09 | 19.83 | 24.04 | 19.22 | 21.54 | 18.73 |
Selling, General & Admin | 18.86 | 18.22 | 18.52 | 17.17 | 15.58 | 14.61 |
Research & Development | 0.3 | 0.38 | 1.24 | 1.17 | 0.38 | 0.05 |
Operating Expenses | 19.9 | 19.35 | 20.25 | 19.46 | 17.08 | 15.49 |
Operating Income | 0.19 | 0.48 | 3.79 | -0.25 | 4.46 | 3.24 |
Interest Expense | -1.82 | -2.07 | -1.86 | -1.24 | -1.08 | -1.38 |
Interest & Investment Income | - | - | 0.11 | 0.12 | - | - |
Other Non Operating Income (Expenses) | 0.03 | 0.05 | 0.01 | 0 | 0 | 0 |
EBT Excluding Unusual Items | -1.61 | -1.53 | 2.04 | -1.36 | 3.39 | 1.86 |
Gain (Loss) on Sale of Investments | -0.3 | -0.81 | 0.77 | 0.05 | -0.04 | -0.01 |
Gain (Loss) on Sale of Assets | - | - | - | - | 0.41 | -0.02 |
Asset Writedown | - | - | - | -13.11 | - | - |
Other Unusual Items | - | - | - | 1.05 | -0.44 | 0.78 |
Pretax Income | -1.91 | -2.34 | 2.8 | -13.36 | 3.32 | 2.61 |
Income Tax Expense | 0.04 | 0.09 | 2.4 | -3.84 | 0.55 | 0.53 |
Net Income | -1.95 | -2.43 | 0.4 | -9.52 | 2.77 | 2.08 |
Net Income to Common | -1.95 | -2.43 | 0.4 | -9.52 | 2.77 | 2.08 |
Net Income Growth | - | - | - | - | 33.02% | -42.52% |
Shares Outstanding (Basic) | 8 | 8 | 8 | 8 | 8 | 8 |
Shares Outstanding (Diluted) | 8 | 8 | 8 | 8 | 8 | 8 |
Shares Change | -0.18% | -1.75% | -1.54% | -1.69% | 1.46% | 2.72% |
EPS (Basic) | -0.24 | -0.30 | 0.05 | -1.14 | 0.33 | 0.26 |
EPS (Diluted) | -0.24 | -0.30 | 0.05 | -1.14 | 0.33 | 0.25 |
EPS Growth | - | - | - | - | 30.95% | -44.44% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 31, 2026 | Nov '25 Nov 30, 2025 | Nov '24 Nov 30, 2024 | Nov '23 Nov 30, 2023 | Nov '22 Nov 30, 2022 | Nov '21 Nov 30, 2021 |
Free Cash Flow | 4.65 | 5.25 | 3.61 | 2.08 | -3.6 | 6.09 |
Free Cash Flow Per Share | 0.58 | 0.65 | 0.44 | 0.25 | -0.42 | 0.73 |
Dividend Per Share | - | 0.400 | 0.250 | - | - | - |
Dividend Growth | - | 60.00% | - | - | - | - |
Gross Margin | 64.53% | 62.82% | 75.15% | 61.31% | 71.02% | 64.85% |
Operating Margin | 0.61% | 1.53% | 11.84% | -0.79% | 14.70% | 11.20% |
Profit Margin | -6.25% | -7.70% | 1.26% | -30.38% | 9.13% | 7.21% |
Free Cash Flow Margin | 14.94% | 16.63% | 11.28% | 6.64% | -11.85% | 21.09% |
EBITDA | 1.16 | 1.47 | 4.48 | 1.15 | 5.96 | 4.27 |
EBITDA Margin | 3.73% | 4.65% | 14.01% | 3.68% | 19.64% | 14.80% |
D&A For EBITDA | 0.97 | 0.99 | 0.69 | 1.4 | 1.5 | 1.04 |
EBIT | 0.19 | 0.48 | 3.79 | -0.25 | 4.46 | 3.24 |
EBIT Margin | 0.61% | 1.53% | 11.84% | -0.79% | 14.70% | 11.20% |
Effective Tax Rate | - | - | 85.66% | - | 16.50% | 20.21% |
Revenue as Reported | 31.13 | 31.57 | 31.99 | 31.34 | 30.34 | 28.88 |
Advertising Expenses | - | 1.09 | 1.07 | 0.95 | 0.76 | 0.84 |